sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Files 2024 Universal Registration Document
GenSight Biologics, a biopharma firm specializing in gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced the filing of its 2024 Universal Registration Document. The document was submitted on April 7, 2025, to the French market authority, AMF. This follows the company's focus on advancing innovative treatments for vision preservation and restoration.
The Universal Registration Document encompasses several key sections, including the 2024 annual financial report, management report, a report on corporate governance, and details of the share buyback program. These components provide a comprehensive overview of the company's operations and strategic objectives for stakeholders and potential investors.
Individuals interested in reviewing these documents can access them on the official website of GenSight Biologics or through the AMF's platform, reinforcing the company's commitment to transparency and investor relations.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.